← Leaderboards
Jason D Huber
University Of Arizona
$4,244,248
Attributed
$5,046,950
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $549.5K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,046,950 · 4
By mechanism
R01$4,889,373 · 3
F32$157,577 · 1
Top collaborators
- Werner Geldenhuys3 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Carol A. Barnes$55,681,144
- Sara N Burke$10,015,092
- Janko Nikolich-Zugich$55,130,377
- Gary L. Wenk$5,101,870
- Andrew Porter Maurer$6,530,240
Others in their field
Top investigators on “Aged”
- Lawrence Corey · Fred Hutchinson Cancer Center$506,603,345
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$351,438,389
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$281,021,854
- George R Seage · Abt Associates, Inc.$218,167,298
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$210,610,900
Research focus
AgedNeuronsResponseMissionIschemic StrokeAcuteRattusReperfusion TherapyInfarctionAreaAttenuatedStrokeNational Institute Of Neurological Disorders And StrokeBlood VesselsFunctional DisorderCerebrumTranslatingApoptosisBrainIschemiaPlayReperfusion InjuryDesignDisability
Grant awards (18)
mitoNEET as a therapeutic target for mitigating ischemic brain injury following MCAO$528,984
R01 · FY2025 · NS · contact PI
mitoNEET as a therapeutic target for mitigating ischemic brain injury following MCAO$526,872
R01 · FY2024 · NS · contact PI
mitoNEET as a therapeutic target for mitigating ischemic brain injury following MCAO$549,549
R01 · FY2023 · NS · contact PI
Therapeutic use of bryostatin-1 to extend tPA time window following MCAO$328,125
R01 · FY2021 · NS · contact PI
Therapeutic use of bryostatin-1 to extend tPA time window following MCAO$328,125
R01 · FY2020 · NS · contact PI
Therapeutic use of bryostatin-1 to extend tPA time window following MCAO$328,271
R01 · FY2019 · NS · contact PI
Therapeutic use of bryostatin-1 to extend tPA time window following MCAO$339,208
R01 · FY2018 · NS · contact PI
Therapeutic use of bryostatin-1 to extend tPA time window following MCAO$306,928
R01 · FY2017 · NS · contact PI
Age influences neuropoietic signaling at the neurovascular unit following stroke$314,059
R01 · FY2012 · NS · contact PI
Age influences neuropoietic signaling at the neurovascular unit following stroke$314,059
R01 · FY2011 · NS · contact PI
Age influences neuropoietic signaling at the neurovascular unit following stroke$317,265
R01 · FY2010 · NS · contact PI
Age influences neuropoietic signaling at the neurovascular unit following stroke$73,500
R01 · FY2010 · NS · contact PI
Age influences neuropoietic signaling at the neurovascular unit following stroke$320,469
R01 · FY2009 · NS · contact PI
Age influences neuropoietic signaling at the neurovascular unit following stroke$313,959
R01 · FY2008 · NS · contact PI
VARIOUS PAIN STATES ON OPIOID TRANSPORT ACROSS THE BBB$38,773
F32 · FY2003 · DA
VARIOUS PAIN STATES ON OPIOID TRANSPORT ACROSS THE BBB$46,192
F32 · FY2002 · DA
VARIOUS PAIN STATES ON OPIOID TRANSPORT ACROSS THE BBB$40,196
F32 · FY2001 · DA
VARIOUS PAIN STATES ON OPIOID TRANSPORT ACROSS THE BBB$32,416
F32 · FY2000 · DA